WO2001074136A3 - Telomerase inhibitor polynucleotides - Google Patents
Telomerase inhibitor polynucleotides Download PDFInfo
- Publication number
- WO2001074136A3 WO2001074136A3 PCT/US2001/010476 US0110476W WO0174136A3 WO 2001074136 A3 WO2001074136 A3 WO 2001074136A3 US 0110476 W US0110476 W US 0110476W WO 0174136 A3 WO0174136 A3 WO 0174136A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleotide
- telomerase inhibitor
- inhibitor polynucleotides
- certain modified
- polynucleotides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001249723A AU2001249723A1 (en) | 2000-03-31 | 2001-03-30 | Telomerase inhibitor polynucleotides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54011900A | 2000-03-31 | 2000-03-31 | |
US09/540,119 | 2000-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001074136A2 WO2001074136A2 (en) | 2001-10-11 |
WO2001074136A3 true WO2001074136A3 (en) | 2003-10-30 |
Family
ID=24154082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/010476 WO2001074136A2 (en) | 2000-03-31 | 2001-03-30 | Telomerase inhibitor polynucleotides |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001249723A1 (en) |
WO (1) | WO2001074136A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070112295A (en) | 1999-09-10 | 2007-11-22 | 제론 코포레이션 | Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
AU2002343527A1 (en) * | 2001-10-22 | 2003-05-06 | University Of Rochester | Telomerase interference |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1432725A4 (en) * | 2002-02-20 | 2005-03-30 | Sirna Therapeutics Inc | RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
EP2900229A4 (en) * | 2012-09-25 | 2016-05-18 | Agency Science Tech & Res | Telomerase inhibitors for use in therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583016A (en) * | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
WO1998028442A1 (en) * | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
-
2001
- 2001-03-30 WO PCT/US2001/010476 patent/WO2001074136A2/en active Application Filing
- 2001-03-30 AU AU2001249723A patent/AU2001249723A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583016A (en) * | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
WO1998028442A1 (en) * | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
Non-Patent Citations (3)
Title |
---|
HAMILTON SUSAN E ET AL: "Cellular delivery of peptide nucleic acids and inhibition of human telomerase.", CHEMISTRY & BIOLOGY (LONDON), vol. 6, no. 6, June 1999 (1999-06-01), pages 343 - 351, XP002242127, ISSN: 1074-5521 * |
NORTON J C ET AL: "INHIBITION OF HUMAN TELOMERASE ACTIVITY BY PEPTIDE NUCLEIC ACIDS", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 14, no. 5, May 1996 (1996-05-01), pages 615 - 619, XP001023086, ISSN: 0733-222X * |
PITTS ANNE E ET AL: "Inhibition of human telomerase by 2'-O-methyl-RNA.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 20, Sept. 29, 1998, pages 11549 - 11554, XP002242128, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001249723A1 (en) | 2001-10-15 |
WO2001074136A2 (en) | 2001-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3024597T3 (en) | 7-deazapurine modified oligonucleotides | |
CA2278715A1 (en) | Aminooxy-modified oligonucleotides | |
HK1154590A1 (en) | Bicyclonucleoside oligonucleotide analogue | |
IL146148A0 (en) | Use of phthalazine derivatives | |
EP0781293A4 (en) | Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides | |
IL145778A0 (en) | Methods and compositions for inhibiting the function of polynucleotide sequences | |
CA2177732A1 (en) | Antisense oligonucleotides having tumorigenicity-inhibiting activity | |
AU6772598A (en) | Recombination of polynucleotide sequences using random or defined primers | |
DE69806003D1 (en) | DNA POLYMERASES THAT HAVE IMPROVED ABILITY TO INSTALL MARKED NUCLEOTIDES | |
WO2001092512A3 (en) | Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides | |
WO2000004158A3 (en) | Compositions and methods for fumonisin detoxification | |
WO2001074136A3 (en) | Telomerase inhibitor polynucleotides | |
WO2001032832A3 (en) | Antisense inhibition of nucleolin expression | |
AU8125098A (en) | Dna methyltransferase genomic sequences and antisense oligonucleotides | |
WO2002102815A3 (en) | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | |
DE69833112D1 (en) | Rna polymerase | |
WO2001040521A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
AU6795201A (en) | Nucleic acid sequences and methods for the modification of plant gene expression | |
IL134083A0 (en) | Process of producing transgenic plants in which flowering is inhibited, and dna sequences used in said process | |
GB2344591B (en) | Thermostable DNA polymerase | |
EP1248635A4 (en) | Antisense modulation of glycogen synthase kinase 3 alpha expression | |
EP1090997A4 (en) | Hcv-derived rna polymerase gene | |
WO2001051670A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
EP1248793A4 (en) | Polynucleotides for inhibiting metastasis and tumor cell growth | |
AU2001233521A1 (en) | Method of designing and selecting polynucleotide sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |